Diamyd Medical (NASDAQ:DMYDY) (STO:DIAMB) announces that its application to initiate European Phase III studies with the therapeutic diabetes vaccine Diamyd®, has been initiated. A submission has been sent today to the Swedish Medicinal Products Agency. Additional submissions will be sent to other European countries. The study is proposed to include approximately 300 patients at 30-50 European clinical sites in 3-5 countries. Principal Investigator for the study will be Professor Ludvigsson, University of Linkoping, Linkoping, Sweden.
